{"transactions":[{"id":941921,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-09T16:39:03.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":82900,"source":{"system":"sec-edgar","filing":"0001104659-26-002511","document":"tm262627-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465926002511/tm262627-6_4seq1.xml","form_type":"4"}},{"id":1111257,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T08:00:33.000Z","date":"2025-06-12","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.48,"value":14800.0,"ownership":{"direct":true},"balance_after":20400,"source":{"system":"sec-edgar","filing":"0001104659-25-059166","document":"tm2517920-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465925059166/tm2517920-1_4seq1.xml","form_type":"4"}},{"id":1182877,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2951,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") represented a contingent right to receive one Company Share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2951},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182876,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":67.77,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":4322},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182875,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":63.79,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":7009},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182874,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":55.48,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16757},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182873,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":43.45,"expiration_date":"2031-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182872,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.02,"expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182871,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":20.39,"expiration_date":"2028-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182870,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":38.35,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182869,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":26.58,"expiration_date":"2025-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1182868,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T17:43:42.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11340,"price":132,"value":1496880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-049636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017025049636/ownership.xml","form_type":"4"}},{"id":1303266,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T17:33:03.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":18500,"derivative":{"exercise_price":0.9525,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-25-003497","document":"tm253166-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465925003497/tm253166-4_4seq1.xml","form_type":"4"}},{"id":1303265,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T17:33:03.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":22900,"source":{"system":"sec-edgar","filing":"0001104659-25-003497","document":"tm253166-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465925003497/tm253166-4_4seq1.xml","form_type":"4"}},{"id":1462361,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-02T20:00:32.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":83,"price":68.49,"value":5684.67,"ownership":{"direct":true},"balance_after":11340,"source":{"system":"sec-edgar","filing":"0000950170-24-080987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024080987/ownership.xml","form_type":"4"}},{"id":1469382,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T18:05:32.000Z","date":"2024-06-23","kind":"exercise","planned":false,"acquired":false,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0000950170-24-077472","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024077472/ownership.xml","form_type":"4"}},{"id":1469381,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T18:05:32.000Z","date":"2024-06-23","kind":"exercise","planned":false,"acquired":true,"shares":1567,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":11257,"source":{"system":"sec-edgar","filing":"0000950170-24-077472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024077472/ownership.xml","form_type":"4"}},{"id":1471848,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T18:00:15.000Z","date":"2024-06-18","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":16.86,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-076380","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024076380/ownership.xml","form_type":"4"}},{"id":1471847,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T18:00:15.000Z","date":"2024-06-18","kind":"sale","planned":true,"acquired":false,"shares":11109,"price":76.07,"value":845061.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.01 to $76.09, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":9690,"source":{"system":"sec-edgar","filing":"0000950170-24-076380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024076380/ownership.xml","form_type":"4"}},{"id":1471846,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T18:00:15.000Z","date":"2024-06-18","kind":"sale","planned":true,"acquired":false,"shares":8891,"price":75.71,"value":673137.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $76.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":20799,"source":{"system":"sec-edgar","filing":"0000950170-24-076380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024076380/ownership.xml","form_type":"4"}},{"id":1471845,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T18:00:15.000Z","date":"2024-06-18","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":16.86,"value":337200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024."}],"balance_after":29690,"source":{"system":"sec-edgar","filing":"0000950170-24-076380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024076380/ownership.xml","form_type":"4"}},{"id":1474861,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T18:00:10.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":4322,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4322,"derivative":{"exercise_price":67.77,"exercise_date":"2025-06-14","expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":4322},"source":{"system":"sec-edgar","filing":"0000950170-24-075077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024075077/ownership.xml","form_type":"4"}},{"id":1474860,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-18T18:00:10.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":2951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025)."}],"balance_after":2951,"derivative":{"underlying":"Common Stock","underlying_shares":2951},"source":{"system":"sec-edgar","filing":"0000950170-24-075077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024075077/ownership.xml","form_type":"4"}},{"id":1552992,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T16:15:19.000Z","date":"2024-03-31","kind":"grant","planned":false,"acquired":true,"shares":79,"price":69.2,"value":5466.8,"ownership":{"direct":true},"balance_after":9690,"source":{"system":"sec-edgar","filing":"0000950170-24-040166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024040166/ownership.xml","form_type":"4"}},{"id":1556733,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T11:52:00.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":11924,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2024."}],"balance_after":48635,"source":{"system":"sec-edgar","filing":"0001628280-24-013923","document":"wk-form4_1711986710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000162828024013923/wk-form4_1711986710.xml","form_type":"4"}},{"id":1611945,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T19:41:57.000Z","date":"2024-02-27","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 21, 2014 and will expire on March 21, 2024. All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":18.56,"expiration_date":"2024-03-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-022485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024022485/ownership.xml","form_type":"4"}},{"id":1611944,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-28T19:41:57.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":10349,"price":73.14,"value":756925.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.0026 to $73.42, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":9611,"source":{"system":"sec-edgar","filing":"0000950170-24-022485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024022485/ownership.xml","form_type":"4"}},{"id":1611943,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-28T19:41:57.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":9651,"price":72.71,"value":701724.21,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0016 to $73.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":19960,"source":{"system":"sec-edgar","filing":"0000950170-24-022485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024022485/ownership.xml","form_type":"4"}},{"id":1611942,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-28T19:41:57.000Z","date":"2024-02-27","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":18.56,"value":371200.0,"ownership":{"direct":true},"balance_after":29611,"source":{"system":"sec-edgar","filing":"0000950170-24-022485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024022485/ownership.xml","form_type":"4"}},{"id":1670746,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T06:00:16.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":10000,"derivative":{"exercise_price":0.5195,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-006381","document":"tm243935-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465924006381/tm243935-6_4seq1.xml","form_type":"4"}},{"id":1670745,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-25T06:00:16.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":10400,"source":{"system":"sec-edgar","filing":"0001104659-24-006381","document":"tm243935-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465924006381/tm243935-6_4seq1.xml","form_type":"4"}},{"id":1691435,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T18:43:01.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":76,"price":71.62,"value":5443.12,"ownership":{"direct":true},"balance_after":9611,"source":{"system":"sec-edgar","filing":"0000950170-24-001303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000095017024001303/ownership.xml","form_type":"4"}},{"id":1693701,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T16:35:35.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":18879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2023."}],"balance_after":36711,"source":{"system":"sec-edgar","filing":"0001628280-24-000210","document":"wk-form4_1704317714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000162828024000210/wk-form4_1704317714.xml","form_type":"4"}},{"id":1770231,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T17:30:25.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":105,"price":52.09,"value":5469.45,"ownership":{"direct":true},"balance_after":9535,"source":{"system":"sec-edgar","filing":"0001209191-23-051143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123051143/doc4.xml","form_type":"4"}},{"id":1770684,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T15:41:54.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":13868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2023."}],"balance_after":17832,"source":{"system":"sec-edgar","filing":"0001121702-23-000056","document":"wk-form4_1696275701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000112170223000056/wk-form4_1696275701.xml","form_type":"4"}},{"id":1835472,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T16:29:50.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":85,"price":63.32,"value":5382.2,"ownership":{"direct":true},"balance_after":9430,"source":{"system":"sec-edgar","filing":"0001209191-23-041084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123041084/doc4.xml","form_type":"4"}},{"id":1837096,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T13:24:27.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":2040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2023."}],"balance_after":3964,"source":{"system":"sec-edgar","filing":"0001628280-23-024201","document":"wk-form4_1688577858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000162828023024201/wk-form4_1688577858.xml","form_type":"4"}},{"id":1843335,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-27T17:12:55.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7009,"derivative":{"exercise_price":63.79,"exercise_date":"2024-06-23","expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":7009},"source":{"system":"sec-edgar","filing":"0001209191-23-039930","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123039930/doc4.xml","form_type":"4"}},{"id":1843334,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-27T17:12:55.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024)."}],"balance_after":1567,"derivative":{"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0001209191-23-039930","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123039930/doc4.xml","form_type":"4"}},{"id":1875208,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T16:39:51.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest and become exercisable in equal quarterly installments over 4 years from 5/25/2023, beginning on 8/25/2023 and ending on 5/25/2027."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These options were granted to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors."}],"balance_after":5000,"derivative":{"exercise_price":2.81,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-23-020149","document":"wk-form4_1685479171.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000162828023020149/wk-form4_1685479171.xml","form_type":"4"}},{"id":1917073,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-19T18:00:22.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":13.05,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-024899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123024899/doc4.xml","form_type":"4"}},{"id":1917072,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-19T18:00:22.000Z","date":"2023-04-17","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":63,"value":630000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":9345,"source":{"system":"sec-edgar","filing":"0001209191-23-024899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123024899/doc4.xml","form_type":"4"}},{"id":1917071,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-19T18:00:22.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":13.05,"value":130500.0,"ownership":{"direct":true},"balance_after":19345,"source":{"system":"sec-edgar","filing":"0001209191-23-024899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123024899/doc4.xml","form_type":"4"}},{"id":1929385,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T17:24:59.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":1642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2023."}],"balance_after":1924,"source":{"system":"sec-edgar","filing":"0001628280-23-010704","document":"wf-form4_168064347214024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000162828023010704/wf-form4_168064347214024.xml","form_type":"4"}},{"id":1927296,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T17:03:52.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":95,"price":54.15,"value":5144.25,"ownership":{"direct":true},"balance_after":9345,"source":{"system":"sec-edgar","filing":"0001209191-23-022799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123022799/doc4.xml","form_type":"4"}},{"id":2032506,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T17:11:52.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":9500,"derivative":{"exercise_price":3.34,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001104659-23-010623","document":"tm235353d3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465923010623/tm235353d3_4seq1.xml","form_type":"4"}},{"id":2032505,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T17:11:52.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":4400,"source":{"system":"sec-edgar","filing":"0001104659-23-010623","document":"tm235353d3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465923010623/tm235353d3_4seq1.xml","form_type":"4"}},{"id":2069025,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T15:56:11.000Z","date":"2022-12-31","kind":"grant","acquired":true,"shares":2109,"price":1.58,"value":3332.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $3,333 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2022."}],"balance_after":2109,"derivative":{"exercise_price":1.67,"exercise_date":"2022-12-31","expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":2109},"source":{"system":"sec-edgar","filing":"0001225198-23-000003","document":"wf-form4_167286575293917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000122519823000003/wf-form4_167286575293917.xml","form_type":"4"}},{"id":2072276,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-03T16:19:59.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":97,"price":52.92,"value":5133.24,"ownership":{"direct":true},"balance_after":9250,"source":{"system":"sec-edgar","filing":"0001209191-23-000197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919123000197/doc4.xml","form_type":"4"}},{"id":2142000,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-05T16:04:03.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":110,"price":46.53,"value":5118.3,"ownership":{"direct":true},"balance_after":9153,"source":{"system":"sec-edgar","filing":"0001209191-22-052716","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122052716/doc4.xml","form_type":"4"}},{"id":2147742,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T16:25:42.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":1601,"price":2.83,"value":4530.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2022."}],"balance_after":1601,"derivative":{"exercise_price":2.99,"exercise_date":"2022-09-30","expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":1601},"source":{"system":"sec-edgar","filing":"0001225198-22-000002","document":"wf-form4_166482853690997.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000122519822000002/wf-form4_166482853690997.xml","form_type":"4"}},{"id":2186781,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-12T18:09:15.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":10000,"derivative":{"exercise_price":13.05,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-045685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122045685/doc4.xml","form_type":"4"}},{"id":2186780,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-12T18:09:15.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":12.45,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-045685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122045685/doc4.xml","form_type":"4"}},{"id":2186779,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-12T18:09:15.000Z","date":"2022-08-11","kind":"sale","acquired":false,"shares":1500,"price":56.8,"value":85200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.775 to $56.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":9043,"source":{"system":"sec-edgar","filing":"0001209191-22-045685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122045685/doc4.xml","form_type":"4"}},{"id":2186778,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-12T18:09:15.000Z","date":"2022-08-11","kind":"sale","acquired":false,"shares":28500,"price":57.15,"value":1628775.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":10543,"source":{"system":"sec-edgar","filing":"0001209191-22-045685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122045685/doc4.xml","form_type":"4"}},{"id":2186777,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-12T18:09:15.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":10000,"price":13.05,"value":130500.0,"ownership":{"direct":true},"balance_after":39043,"source":{"system":"sec-edgar","filing":"0001209191-22-045685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122045685/doc4.xml","form_type":"4"}},{"id":2186776,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-12T18:09:15.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":20000,"price":12.45,"value":249000.0,"ownership":{"direct":true},"balance_after":29043,"source":{"system":"sec-edgar","filing":"0001209191-22-045685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122045685/doc4.xml","form_type":"4"}},{"id":2214193,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T16:08:51.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":108,"price":57.08,"value":6164.64,"ownership":{"direct":true},"balance_after":9043,"source":{"system":"sec-edgar","filing":"0001209191-22-040571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122040571/doc4.xml","form_type":"4"}},{"id":2217584,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:46:38.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":2134,"price":2.12,"value":4524.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2022."}],"balance_after":2134,"derivative":{"exercise_price":2.25,"exercise_date":"2022-06-30","expiration_date":"2032-06-30","underlying":"Stock Option (right to buy)","underlying_shares":2134},"source":{"system":"sec-edgar","filing":"0001121702-22-000030","document":"wf-form4_165670837395692.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000112170222000030/wf-form4_165670837395692.xml","form_type":"4"}},{"id":2233836,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T17:01:05.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":16757,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16757,"derivative":{"exercise_price":55.48,"exercise_date":"2023-06-09","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16757},"source":{"system":"sec-edgar","filing":"0001209191-22-036372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122036372/doc4.xml","form_type":"4"}},{"id":2255531,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T09:18:03.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options will vest and become exercisable in equal quarterly installments over 4 years from 5/25/2022, beginning on 8/25/2022 and ending on 5/25/2026."}],"balance_after":5000,"derivative":{"exercise_price":2.69,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-22-003144","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911022003144/edgar.xml","form_type":"4"}},{"id":2308959,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-04T17:41:35.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":908,"price":4.99,"value":4530.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2022."}],"balance_after":908,"derivative":{"exercise_price":5.3,"exercise_date":"2022-03-31","expiration_date":"2032-03-31","underlying":"Common Stock","underlying_shares":908},"source":{"system":"sec-edgar","filing":"0001179110-22-002550","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911022002550/edgar.xml","form_type":"4"}},{"id":2307616,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-04T16:11:01.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":126,"price":61.19,"value":7709.94,"ownership":{"direct":true},"balance_after":8935,"source":{"system":"sec-edgar","filing":"0001209191-22-022323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122022323/doc4.xml","form_type":"4"}},{"id":2418967,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T17:06:44.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":7125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":7125,"derivative":{"exercise_price":5.34,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":7125},"source":{"system":"sec-edgar","filing":"0001104659-22-010397","document":"tm225088-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465922010397/tm225088-4_4seq1.xml","form_type":"4"}},{"id":2418966,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-01T17:06:44.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":1900,"source":{"system":"sec-edgar","filing":"0001104659-22-010397","document":"tm225088-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465922010397/tm225088-4_4seq1.xml","form_type":"4"}},{"id":2448001,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T21:52:13.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":148,"price":52.34,"value":7746.32,"ownership":{"direct":true},"balance_after":8809,"source":{"system":"sec-edgar","filing":"0001209191-22-001347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919122001347/doc4.xml","form_type":"4"}},{"id":2454708,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-03T16:48:27.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":976,"price":4.64,"value":4528.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2021."}],"balance_after":976,"derivative":{"exercise_price":4.92,"exercise_date":"2021-12-31","expiration_date":"2031-12-31","underlying":"Common Stock","underlying_shares":976},"source":{"system":"sec-edgar","filing":"0001179110-22-000015","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911022000015/edgar.xml","form_type":"4"}},{"id":2551521,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-04T16:23:03.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":215,"price":37.28,"value":8015.2,"ownership":{"direct":true},"balance_after":8661,"source":{"system":"sec-edgar","filing":"0001209191-21-058949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919121058949/doc4.xml","form_type":"4"}},{"id":2552540,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-10-04T14:53:57.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":801,"price":5.66,"value":4533.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2021."}],"balance_after":801,"derivative":{"exercise_price":5.99,"exercise_date":"2021-09-30","expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":801},"source":{"system":"sec-edgar","filing":"0001179110-21-009134","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911021009134/edgar.xml","form_type":"4"}},{"id":2643951,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T16:55:02.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":173,"price":40.82,"value":7061.86,"ownership":{"direct":true},"balance_after":8446,"source":{"system":"sec-edgar","filing":"0001209191-21-045038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919121045038/doc4.xml","form_type":"4"}},{"id":2648228,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T16:23:32.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":562,"price":8.06,"value":4529.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2021."}],"balance_after":562,"derivative":{"exercise_price":8.53,"exercise_date":"2021-06-30","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001179110-21-007250","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911021007250/edgar.xml","form_type":"4"}},{"id":2658547,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T16:19:03.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":43.45,"exercise_date":"2022-06-21","expiration_date":"2031-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-042386","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919121042386/doc4.xml","form_type":"4"}},{"id":2695692,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-26T09:59:46.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options will vest and become exercisable in equal quarterly installments over 4 years from 5/24/2021, beginning on 8/24/2021 and ending on 5/24/2025."}],"balance_after":5000,"derivative":{"exercise_price":7.96,"expiration_date":"2031-05-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-21-005917","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911021005917/edgar.xml","form_type":"4"}},{"id":2760686,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T17:26:41.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":208,"price":33.93,"value":7057.44,"ownership":{"direct":true},"balance_after":8273,"source":{"system":"sec-edgar","filing":"0001209191-21-024723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919121024723/doc4.xml","form_type":"4"}},{"id":2762033,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T11:19:50.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":383,"price":11.84,"value":4534.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2021."}],"balance_after":383,"derivative":{"exercise_price":12.54,"exercise_date":"2021-03-31","expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":383},"source":{"system":"sec-edgar","filing":"0001179110-21-004027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911021004027/edgar.xml","form_type":"4"}},{"id":2802758,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-08T16:28:49.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the earlier of (x) March 4, 2022 (the first anniversary of the date of grant) or (y) the business day prior to the 2022 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":7500,"derivative":{"exercise_price":8,"expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-033296","document":"tm218923d4_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465921033296/tm218923d4_4.xml","form_type":"4"}},{"id":2919622,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T18:05:40.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":222,"price":31.8,"value":7059.6,"ownership":{"direct":true},"balance_after":8065,"source":{"system":"sec-edgar","filing":"0001209191-21-001503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919121001503/doc4.xml","form_type":"4"}},{"id":2926003,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-04T19:10:23.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":818,"price":5.54,"value":4531.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2020."}],"balance_after":818,"derivative":{"exercise_price":5.78,"exercise_date":"2020-12-31","expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":818},"source":{"system":"sec-edgar","filing":"0001179110-21-000068","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911021000068/edgar.xml","form_type":"4"}},{"id":3015716,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-02T16:24:33.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":276,"price":25.66,"value":7082.16,"ownership":{"direct":true},"balance_after":7843,"source":{"system":"sec-edgar","filing":"0001209191-20-053136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919120053136/doc4.xml","form_type":"4"}},{"id":3016742,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-02T11:04:15.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":624,"price":7.26,"value":4530.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2020."}],"balance_after":624,"derivative":{"exercise_price":7.77,"exercise_date":"2020-09-30","expiration_date":"2030-09-30","underlying":"Common Stock","underlying_shares":624},"source":{"system":"sec-edgar","filing":"0001179110-20-010076","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911020010076/edgar.xml","form_type":"4"}},{"id":3091156,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T19:12:50.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":275,"price":25.67,"value":7059.25,"ownership":{"direct":true},"balance_after":7567,"source":{"system":"sec-edgar","filing":"0001209191-20-040693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919120040693/doc4.xml","form_type":"4"}},{"id":3092620,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-02T13:02:25.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":777,"price":5.84,"value":4537.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as amember of its Board of Directors and/or a committee thereof during the second quarter of 2020."}],"balance_after":777,"derivative":{"exercise_price":6.26,"exercise_date":"2020-06-30","expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":777},"source":{"system":"sec-edgar","filing":"0001179110-20-007866","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911020007866/edgar.xml","form_type":"4"}},{"id":3130929,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T15:58:35.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options will vest and become exercisable in equal quarterly installments over 4 years from 5/28/2020, beginning on 8/28/2020 and ending on 5/28/2024."}],"balance_after":5000,"derivative":{"exercise_price":5.86,"expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-20-006710","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911020006710/edgar.xml","form_type":"4"}},{"id":3131892,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-28T19:13:00.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":22.02,"exercise_date":"2021-05-27","expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-032745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919120032745/doc4.xml","form_type":"4"}},{"id":3185995,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-02T17:55:55.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":460,"price":15.37,"value":7070.2,"ownership":{"direct":true},"balance_after":7292,"source":{"system":"sec-edgar","filing":"0001209191-20-022753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919120022753/doc4.xml","form_type":"4"}},{"id":3187002,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-02T16:34:49.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":1294,"price":3.5,"value":4529.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"All share numbers reported reflect the 1-for-40 reverse stock split effected on January 15, 2020."}],"balance_after":1294,"derivative":{"exercise_price":3.77,"exercise_date":"2020-03-31","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":1294},"source":{"system":"sec-edgar","filing":"0001179110-20-004502","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000117911020004502/edgar.xml","form_type":"4"}},{"id":3208428,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-16T21:19:20.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the earlier of (x) March 12, 2021 (the first anniversary of the date of grant) or (y) the business day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":6500,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-12","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001104659-20-034288","document":"tm2012902-4_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000110465920034288/tm2012902-4_form4.xml","form_type":"4"}},{"id":3299108,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299107,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299106,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2023-12-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299105,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299104,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299103,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2026-01-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299102,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.59,"expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3299101,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-29T16:16:37.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":6.3,"value":252000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the merger agreement (the \"Merger Agreement\") among Achillion Pharmaceuticals, Inc. (\"Achillion\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-000677","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000677/primarydocument.xml","form_type":"4"}},{"id":3322116,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T21:13:18.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":170,"price":34.31,"value":5832.7,"ownership":{"direct":true},"balance_after":6832,"source":{"system":"sec-edgar","filing":"0001209191-20-001464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919120001464/doc4.xml","form_type":"4"}},{"id":3335394,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-19T17:33:40.000Z","date":"2019-12-18","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":3.28,"expiration_date":"2019-12-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-19-006193","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019006193/primarydocument.xml","form_type":"4"}},{"id":3335393,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-19T17:33:40.000Z","date":"2019-12-18","kind":"exercise","acquired":true,"shares":20000,"price":3.28,"value":65600.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001562180-19-006193","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019006193/primarydocument.xml","form_type":"4"}},{"id":3401387,"issuer":{"id":88195,"kind":"organization","name":"YIELD10 BIOSCIENCE, INC.","symbol":"YTEN"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-02T18:18:11.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":9845,"price":0.46,"value":4528.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2019."}],"balance_after":9845,"derivative":{"exercise_price":0.5,"exercise_date":"2019-09-30","expiration_date":"2029-09-30","underlying":"Common Stock","underlying_shares":9845},"source":{"system":"sec-edgar","filing":"0001104659-19-052674","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121702/000110465919052674/a4.xml","form_type":"4"}},{"id":3400572,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":69643,"kind":"person","name":"VAN NOSTRAND ROBERT L","position":1,"cik":"0001225198","reported_name":"VAN NOSTRAND ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-02T17:32:44.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":780,"price":7.47,"value":5826.6,"ownership":{"direct":true},"balance_after":6662,"source":{"system":"sec-edgar","filing":"0001209191-19-051853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225198/000120919119051853/doc4.xml","form_type":"4"}}],"next_cursor":"2019-10-02T17:32:44.000000Z,3400572"}